New combo therapy aims to shrink unresectable bile duct tumors

NCT ID NCT07364305

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a treatment for people with advanced bile duct cancer (ICC) that cannot be removed by surgery. The treatment combines chemotherapy given directly into the liver (HAIC) with immunotherapy drugs. The goal is to see if this combination can shrink tumors enough to allow surgery or improve outcomes. About 50 participants will be enrolled.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer intrahepatic cholangiocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Shanghai Eastern Hepatobiliary Surgery Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 200438, China

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••